【摘要】 目的 研究晚期非小细胞肺癌（NSCLC）接受靶向治疗中应用吉非替尼的临床效果。方法 52例晚期非小细胞肺癌患者,按照治疗模式的差异性分为对照组与观察组,每组26例。对照组采用常规治疗模式,观察组在对照组基础上采用吉非替尼治疗模式。比较两组临床疗效、血清肿瘤标志物、细胞因子、毒副作用发生率。结果 观察组的治疗总有效率92.31%高于对照组的65.38%（P<0.05）。治疗后,观察组β₂微球蛋白（1.42±0.38）mg/L、神经烯醇化酶（8.34±1.45）μg/L、糖抗原125（25.07±6.49）U/ml、癌胚抗原（18.59±4.16）μg/L明显低于对照组的（2.23±0.55）mg/L、（20.76±3.42）μg/L、（41.88±9.65）U/ml、（30.31±4.19）μg/L（P<0.05）。治疗后,观察组白细胞介素-17（5.04±1.16）pg/ml、白细胞介素-8（18.52±0.72）pg/ml、肿瘤坏死因子-α（33.78±2.88）pg/ml低于对照组的（6.39±1.38）、（22.26±0.85）、（39.30±2.19）pg/ml（P<0.05）。观察组毒副作用发生率11.54%明显低于对照组的38.46%（P<0.05）。结论 对接受靶向治疗的晚期非小细胞肺癌患者应用吉非替尼治疗的效果显著,可有效改善患者的预后。更多还原

【Abstract】 Objective To study the clinical efficacy of gefitinib in targeted therapy for advanced nonsmall cell lung cancer（NSCLC）. Methods 52 patients with advanced non-small cell lung cancer were divided into a control group and an observation group according to different treatment modes, with 26 cases in each group. The control group was given conventional treatment mode, and the observation group was given gefitinib treatment mode based on the control group. The clinical efficacy, serum tumor markers, cytokines, and incidence of toxic side effects were compared between the two groups. Results The total effective rate of 92.31% in the observation group was higher than 65.38% in the control group（P<0.05）. After treatment, the observation group had β₂ microglobulin of（1.42±0.38） mg/L, neuro-specific enolase of（8.34±1.45） μg/L, carbohydrate antigen 125 of（25.07±6.49） U/ml, carcinoembryonic antigen of（18.59±4.16） μg/L, which were significantly lower than（2.23±0.55） mg/L,（20.76±3.42） μg/L,（41.88±9.65） U/ml,（30.31±4.19） μg/L in the control group（P<0.05）.After treatment, the observation group had interleukin-17 of（5.04±1.16） pg/ml, interleukin-8 of（18.52±0.72） pg/ml and tumor necrosis factor-α of（33.78±2.88） pg/ml, which were lower than（6.39±1.38）,（22.26±0.85） and（39.30±2.19） pg/ml in the control group（P<0.05）. The incidence of toxic side effects in the observation group was 11.54%, which was significantly lower than 38.46% in the control group（P<0.05）.Conclusion The application of gefitinib to advanced non-small cell lung cancer patients receiving targeted therapy has significant therapeutic results and can effectively improve the patient’s prognosis.更多还原